Compare McKesson Corporation (MCK) vs Block Inc (XYZ) Price & Performance

McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.

McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.

XYZ trades at $75.21, down 1.13% on the day, with a bearish technical signal but strong analyst support. The company reported mixed earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 results pending. Revenue growth has been steady, reaching $24.19B in 2025, though net income margin compressed to 1.43%. Cash flow trends show volatility, with 2025 net cash flow negative $749.24M due to heavy investing activity.

The stock offers potential upside to the consensus price target of $97.47, supported by a 76.9% buy rating from analysts. However, risks include high P/E of 134.34, margin pressures, and insider selling. Positive developments include expanding partnerships and a potential federal trust bank application, which could enhance profitability long-term.